Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) FCF Margin (2016 - 2025)

Historic FCF Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 98.56%.

  • Lineage Cell Therapeutics' FCF Margin rose 575400.0% to 98.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 193.0%, marking a year-over-year increase of 714300.0%. This contributed to the annual value of 249.05% for FY2024, which is 778400.0% up from last year.
  • Lineage Cell Therapeutics' FCF Margin amounted to 98.56% in Q3 2025, which was up 575400.0% from 200.83% recorded in Q2 2025.
  • Lineage Cell Therapeutics' FCF Margin's 5-year high stood at 417.38% during Q1 2022, with a 5-year trough of 1901.53% in Q1 2021.
  • In the last 5 years, Lineage Cell Therapeutics' FCF Margin had a median value of 234.0% in 2024 and averaged 355.91%.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' FCF Margin crashed by -9217700bps in 2021, and later soared by 23189100bps in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' FCF Margin stood at 12.04% in 2021, then tumbled by -3495bps to 432.74% in 2022, then soared by 32bps to 292.62% in 2023, then rose by 20bps to 234.0% in 2024, then surged by 58bps to 98.56% in 2025.
  • Its FCF Margin was 98.56% in Q3 2025, compared to 200.83% in Q2 2025 and 331.76% in Q1 2025.